Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marjie L Hard

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Placenta|February 5, 2003
Binding of acetaldehyde to human and Guinea pig placentae in vitroMarjie L Hard, Umar Iqbal, James F Brien, et al.
The Journal of Laboratory and Clinical Medicine|January 26, 2005
Gene-expression analysis after alcohol exposure in the developing mouseMarjie L Hard, Mohamed Abdolell, Brian H Robinson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 15, 2009
A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairmentRonald MacFarland, Marjie L Hard, Robert Scarborough, et al.
Journal of Clinical Psychopharmacology|March 29, 2017
Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With SchizophreniaMarjie L Hard, Richard J Mills, Brian M Sadler, et al.
European Journal of Drug Metabolism and Pharmacokinetics|June 27, 2018
Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole LauroxilMarjie L Hard, Angela Y Wehr, Brian M Sadler, et al.
Journal of Cardiovascular Pharmacology|April 3, 2014
Lack of clinical pharmacodynamic and pharmacokinetic drug-drug interactions between warfarin and the antisense oligonucleotide mipomersenZhaoyang Li, Marjie L Hard, John S Grundy, et al.
Journal of Clinical Psychopharmacology|July 18, 2018
Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for SchizophreniaMarjie L Hard, Angela Y Wehr, Yangchun Du, et al.
Therapeutic Advances in Psychopharmacology|July 17, 2019
Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal<sup>®</sup> Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxilMarjie L Hard, Angela Wehr, Lisa von Moltke, et al.
CNS Drugs|June 10, 2017
Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic ModelMarjie L Hard, Richard J Mills, Brian M Sadler, et al.
Clinical Pharmacology in Drug Development|June 9, 2021
Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult VolunteersXiaoshu Dai, Michael D Karol, Matthew Hitron, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Placenta|February 5, 2003
Binding of acetaldehyde to human and Guinea pig placentae in vitroMarjie L Hard, Umar Iqbal, James F Brien, et al.
The Journal of Laboratory and Clinical Medicine|January 26, 2005
Gene-expression analysis after alcohol exposure in the developing mouseMarjie L Hard, Mohamed Abdolell, Brian H Robinson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 15, 2009
A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairmentRonald MacFarland, Marjie L Hard, Robert Scarborough, et al.
Journal of Clinical Psychopharmacology|March 29, 2017
Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With SchizophreniaMarjie L Hard, Richard J Mills, Brian M Sadler, et al.
European Journal of Drug Metabolism and Pharmacokinetics|June 27, 2018
Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole LauroxilMarjie L Hard, Angela Y Wehr, Brian M Sadler, et al.
Journal of Cardiovascular Pharmacology|April 3, 2014
Lack of clinical pharmacodynamic and pharmacokinetic drug-drug interactions between warfarin and the antisense oligonucleotide mipomersenZhaoyang Li, Marjie L Hard, John S Grundy, et al.
Journal of Clinical Psychopharmacology|July 18, 2018
Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for SchizophreniaMarjie L Hard, Angela Y Wehr, Yangchun Du, et al.
Therapeutic Advances in Psychopharmacology|July 17, 2019
Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal<sup>®</sup> Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxilMarjie L Hard, Angela Wehr, Lisa von Moltke, et al.
CNS Drugs|June 10, 2017
Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic ModelMarjie L Hard, Richard J Mills, Brian M Sadler, et al.
Clinical Pharmacology in Drug Development|June 9, 2021
Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult VolunteersXiaoshu Dai, Michael D Karol, Matthew Hitron, et al.
Pageof 2